Quantitative analysis for TScan Therapeutics, Inc. (TCRX) — Health Care: AI-powered alpha score, Benjamin Graham intrinsic value, ML-based forecast, technical and fundamental signals, and insider activity.
Current Q-Score verdict: Unrated (50.0). 29 signals analyzed (25 differentiated alt-data).
TCRX stock price is tracked daily for technical and fundamental analysis. The data below shows recent trading activity used in trend analysis, momentum calculation, and entry/exit signals.
| Date | High | Low | Close |
|---|---|---|---|
| 2026-04-28 | $1.32 | $1.25 | $1.26 |
| 2026-05-08 | $1.34 | $1.23 | $1.26 |
| 2026-05-20 | $1.02 | $0.96 | $0.99 |
| 2026-06-02 | $1.07 | $0.97 | $0.98 |
| 2026-06-12 | $0.96 | $0.91 | $0.91 |
| 2026-06-25 | $0.90 | $0.82 | $0.84 |
| 2026-07-08 | $1.28 | $1.03 | $1.26 |
| 2026-07-20 | $0.97 | $0.89 | $0.92 |
| 2026-07-30 | $0.78 | $0.74 | $0.76 |
| 2026-08-12 | $0.79 | $0.75 | $0.77 |
| 2026-08-24 | $0.80 | $0.77 | $0.80 |
| 2026-09-03 | $0.40 | $0.35 | $0.37 |
How TScan Therapeutics, Inc. stacks up against same-sector peers on market capitalization and alpha scores:
| Ticker | Company | Market Cap | Alpha Score |
|---|---|---|---|
| FLNA | Filana Therapeutics, Inc. | $60M | — |
| BGM | BGM Group Ltd. | $59M | — |
| PDSB | PDS Biotechnology Corporation | $57M | — |
| CBUS | Cibus, Inc. | $65M | — |
View all Health Care stocks by valuation and signals →
TScan Therapeutics, Inc. (TCRX) scores Unrated (50.0), and the composite conceals a 97-point disagreement between its dimensions. It is strongest on competitive moat at 99 and analyst consensus at 79, and weakest on technicals at 2. A stock can carry competitive moat that high while technicals sits at 2; the composite averages that tension away, which is why the breakdown is worth reading before the headline number. See Q-Score methodology for how these dimensions are weighted and combined.
| Dimension | Score |
|---|---|
| competitive moat | 99 |
| analyst consensus | 79 |
| technicals | 2 |
StoQuant analyzes 29 signals (25 alt-data). Alternative data sources (FDA approvals, GitHub activity, SEC filings, App Store ratings) complement traditional financial metrics.
All StoQuant signals are explained in our knowledge base:
Health Care Hub — Top performers and valuation outliers in Health Care
Get daily updates on TScan Therapeutics, Inc. (TCRX): Q-Score changes, insider transactions, forecast shifts, sector rotation, and macroeconomic context. The StoQuant digest curates the most material signals for your watchlist — free, no account required.
See a sample digest • Unsubscribe anytime • Privacy policy
StoQuant is a quantitative stock research platform powered by AI scoring, fundamental analysis, and institutional-grade signals. We cover 3,600+ US-listed equities with daily updates on valuations, earnings quality, insider flow, and ML-based return forecasts. Learn more about us.
Share this stock's latest Q-Score and alpha score on your website, GitHub README, or blog. The SVG badge auto-updates daily:
<a href="https://stoquant.com/research/TCRX"><img src="https://stoquant.com/badge/TCRX.svg" alt="TScan Therapeutics, Inc. (TCRX) Q-Score and Alpha on StoQuant" width="240" height="64" /></a>
StoQuant research is generated algorithmically using public market data, SEC filings, news feeds, and proprietary ML models. Not investment advice. Past performance does not guarantee future results.
Weekly Q-Score signals and insider buying activity on our highest-conviction stock picks. Email only, no account needed. See a sample digest.